Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
NCT ID: NCT05726383
Last Updated: 2026-02-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
32 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-05-14
Study Completion Date
2027-05-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions.
The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy
NCT00052325
Lung Cancer
UNKNOWN
PHASE2
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
NCT00518206
Melanoma
COMPLETED
PHASE2
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
NCT01961115
Mucosal Melanoma
Recurrent Melanoma
Recurrent Uveal Melanoma
+8 more
COMPLETED
PHASE2
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
NCT03051477
Solid Tumor
COMPLETED
PHASE1
Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
NCT00006354
Unspecified Adult Solid Tumor, Protocol Specific
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions.
Iscador® P is to be injected subcutaneously (abdominal) 3 times/week. All patients will start with Series 0 (0.01mg, 0.01mg, 0.1mg, 0.1mg, 1mg, 1mg, 1mg). If tolerated, they will receive this series for 2 consecutive boxes (2 x 7 vials per box). This will then be followed by Series 1 (0.1mg, 0.1mg, 1mg, 1mg, 10mg, 10mg, 10mg), which will be administered for the following 2 consecutive boxes (2 x 7 vials per box). If tolerated, patients will proceed to Series 2 (1mg, 1mg, 10mg, 10mg, 20mg, 20mg 20mg), which will be continued through week 52 (13 cycles).
The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
Iscador® P is to be injected subcutaneously (abdominal) 3 times/week. All patients will start with Series 0 (0.01mg, 0.01mg, 0.1mg, 0.1mg, 1mg, 1mg, 1mg). If tolerated, they will receive this series for 2 consecutive boxes (2 x 7 vials per box). This will then be followed by Series 1 (0.1mg, 0.1mg, 1mg, 1mg, 10mg, 10mg, 10mg), which will be administered for the following 2 consecutive boxes (2 x 7 vials per box). If tolerated, patients will proceed to Series 2 (1mg, 1mg, 10mg, 10mg, 20mg, 20mg 20mg), which will be continued through week 52 (13 cycles).
The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Osteogenic Sarcoma Recurrent
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Arm - Iscador*P
Each Iscador® P therapy begins with a dose finding phase related to the drug' immunogenicity. In this phase, gradually increasing doses are used to determine the optimum individual dose response of the patient and to prevent excessive toxicity. The Iscador® P will be administered three times per week by subcutaneous injections (M,W,F) into the subcutaneous tissue of the thigh or abdomen. Treatment is administered according to a series of escalating doses that are given each of the three days in a week for 7 doses. There are 3 different series (Series 0, 1, and 2) and there are 7 dose vials in each series. Once the patient has reached their maximum tolerated dosing series, that series is used as the treatment regimen for the remaining weeks to a total duration of 52 weeks (13 cycles) or until disease progression. Each cycle is 4 weeks.
Group Type
EXPERIMENTAL
Iscador*P
Intervention Type
DRUG
Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iscador*P
Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologic diagnosis of osteosarcoma.
* Patients with at least one episode of relapse in the lung (without limitation of number of episodes), following surgical resection of all gross metastatic disease.
* Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within 8 weeks prior to study enrollment. Note: If surgery related changes such as atelectasis are seen on the post-operative CT scan, patients will remain eligible to enroll as long as the operating surgeon believes that all sites of metastases were resected. Patients with positive microscopic margins will be eligible to enroll.
* Pathological confirmation of metastases from at least one of the resected sites.
* Age ≥ 8 years of age and \<30 years of age.
* Patients must be able to receive subcutaneous injections.
* Performance level as measured by Karnofsky ≥60% for patients \> 16 years of age or Lansky ≥ 60% for patients ≤ 16 years of age.
* Female patients of childbearing potential must have a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required. If a patient is of childbearing potential the patient must agree to use effective contraception during the study and for 120 days after the last dose of study drug.
* If male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug
* Life expectancy of \> two months
* Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade \<1 (except alopecia, cytopenia, or neuropathy). If a patient underwent major surgery or radiation therapy of \>30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
* Patients must meet the following laboratory criteria
1. Adequate hepatic function with serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN) and total serum bilirubin \< 2.5 times the ULN or Direct bilirubin ≤ ULN for patients with total bilirubin levels \> 2.5 X ULN
2. Absolute neutrophil count ≥ 500/dL
3. Platelet count ≥ 20,000/L
4. Creatinine ≤ 1.5 X the ULN or measurement of calculated creatinine clearance (CrCl) ≥ 60 ml/minute
* Patients with at least one episode of relapse in the lung (without limitation of number of episodes), following surgical resection of all gross metastatic disease.
* Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within 8 weeks prior to study enrollment. Note: If surgery related changes such as atelectasis are seen on the post-operative CT scan, patients will remain eligible to enroll as long as the operating surgeon believes that all sites of metastases were resected. Patients with positive microscopic margins will be eligible to enroll.
* Pathological confirmation of metastases from at least one of the resected sites.
* Age ≥ 8 years of age and \<30 years of age.
* Patients must be able to receive subcutaneous injections.
* Performance level as measured by Karnofsky ≥60% for patients \> 16 years of age or Lansky ≥ 60% for patients ≤ 16 years of age.
* Female patients of childbearing potential must have a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required. If a patient is of childbearing potential the patient must agree to use effective contraception during the study and for 120 days after the last dose of study drug.
* If male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug
* Life expectancy of \> two months
* Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade \<1 (except alopecia, cytopenia, or neuropathy). If a patient underwent major surgery or radiation therapy of \>30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
* Patients must meet the following laboratory criteria
1. Adequate hepatic function with serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN) and total serum bilirubin \< 2.5 times the ULN or Direct bilirubin ≤ ULN for patients with total bilirubin levels \> 2.5 X ULN
2. Absolute neutrophil count ≥ 500/dL
3. Platelet count ≥ 20,000/L
4. Creatinine ≤ 1.5 X the ULN or measurement of calculated creatinine clearance (CrCl) ≥ 60 ml/minute
Exclusion Criteria
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:
* Another known malignancy other than osteosarcoma that is progressing or requires active treatment.
* Any prior history of other cancer within the prior 5 years with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia \[CIN\]/cervical carcinoma in situ or melanoma in situ).
* Active infection requiring systemic therapy.
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* New recurrence of osteosarcoma metastasis in any location other than lung
* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
* Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
* Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid \[qualitative\]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \[HBc Ab\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to study treatment. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
* Known history of chronic granulomatous diseases, florid autoimmune diseases, diseases treated with immunosuppressive drugs, hyperthyroidism with tachycardia, tuberculosis, parasitosis or Crohn's disease.
* If female, is pregnant or breastfeeding.
* Patients must have had no systemic chemotherapy or immunotherapy in the three weeks prior to enrollment and must have fully recovered from side effects of prior treatment at enrollment.
* Patients may not receive any additional chemotherapeutic agent (either conventional or experimental) while on study.
* Patients must not have received radiation therapy for up to two weeks prior to enrollment.
* Patients must have no known prior allergy to Iscador® P or any other Viscum album products.
* Patients must not receive concomitant treatment with immunostimulant or immunosuppressive drugs.
* Another known malignancy other than osteosarcoma that is progressing or requires active treatment.
* Any prior history of other cancer within the prior 5 years with the exception of adequately treated basal cell carcinoma or cervical intraepithelial neoplasia \[CIN\]/cervical carcinoma in situ or melanoma in situ).
* Active infection requiring systemic therapy.
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* New recurrence of osteosarcoma metastasis in any location other than lung
* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.
* Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
* Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid \[qualitative\]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \[HBc Ab\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to study treatment. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
* Known history of chronic granulomatous diseases, florid autoimmune diseases, diseases treated with immunosuppressive drugs, hyperthyroidism with tachycardia, tuberculosis, parasitosis or Crohn's disease.
* If female, is pregnant or breastfeeding.
* Patients must have had no systemic chemotherapy or immunotherapy in the three weeks prior to enrollment and must have fully recovered from side effects of prior treatment at enrollment.
* Patients may not receive any additional chemotherapeutic agent (either conventional or experimental) while on study.
* Patients must not have received radiation therapy for up to two weeks prior to enrollment.
* Patients must have no known prior allergy to Iscador® P or any other Viscum album products.
* Patients must not receive concomitant treatment with immunostimulant or immunosuppressive drugs.
Minimum Eligible Age
8 Years
Maximum Eligible Age
30 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Sponsor Role
collaborator
Iscador AG, Arlesheim, Switzerland.
UNKNOWN
Sponsor Role
collaborator
Tackle Kids Cancer
UNKNOWN
Sponsor Role
collaborator
Susan Zabransky Hughes Foundation
UNKNOWN
Sponsor Role
collaborator
Hackensack Meridian Health
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katharine Offer, MD
Role: PRINCIPAL_INVESTIGATOR
Hackensack Meridian Health
Karen Moody, MD
Role: PRINCIPAL_INVESTIGATOR
MD Anderson
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hackensack University Medical Center
Hackensack, New Jersey, United States
Site Status
RECRUITING
M.D. Anderson Children's Cancer Hospital
Houston, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Jung ML, Baudino S, Ribereau-Gayon G, Beck JP. Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett. 1990 May 30;51(2):103-8. doi: 10.1016/0304-3835(90)90044-x.
Reference Type
BACKGROUND
Boye K, Longhi A, Guren T, Lorenz S, Naess S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Londalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021 Sep;70(9):2617-2624. doi: 10.1007/s00262-021-02876-w. Epub 2021 Feb 12.
Reference Type
BACKGROUND
Bussing A, Regnery A, Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett. 1995 Aug 1;94(2):199-205. doi: 10.1016/0304-3835(95)03850-v.
Reference Type
BACKGROUND
Bussing A, Stumpf C, Troger W, Schietzel M. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res. 2007 Jul-Aug;27(4C):2903-10.
Reference Type
BACKGROUND
Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2005 Nov 15;104(10):2214-21. doi: 10.1002/cncr.21417.
Reference Type
BACKGROUND
Gabius HJ, Gabius S, Joshi SS, Koch B, Schroeder M, Manzke WM, Westerhausen M. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med. 1994 Feb;60(1):2-7. doi: 10.1055/s-2006-959396.
Reference Type
BACKGROUND
Gabriel AP, Mercado CP. Data retention after a patient withdraws consent in clinical trials. Open Access J Clin Trials. 2011 Apr;3:15-19. doi: 10.2147/OAJCT.S13960.
Reference Type
BACKGROUND
Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008 Apr 16;2008(2):CD003297. doi: 10.1002/14651858.CD003297.pub2.
Reference Type
BACKGROUND
Heinzerling L, von Baehr V, Liebenthal C, von Baehr R, Volk HD. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol. 2006 Jul;26(4):347-59. doi: 10.1007/s10875-006-9023-5. Epub 2006 May 17.
Reference Type
BACKGROUND
Klein R, Classen K, Berg PA, Ludtke R, Werner M, Huber R. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Eur J Med Res. 2002 Apr 30;7(4):155-63.
Reference Type
BACKGROUND
Klein R et al. Effects of mistletoe extracts on immunocompetent cells in vitro and in vivo and their relevance for the therapy of tumor diseases and other clinical entities. In Scheer R et al.(Ed): Forschritte in der Mistletherapie. KVC Verlag, Essen, 207-221. 2005
Reference Type
BACKGROUND
Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O 3rd, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, Grier HE, Weigel B, Blaney SM, Gorlick R, Janeway KA. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 Sep 1;34(25):3031-8. doi: 10.1200/JCO.2015.65.5381. Epub 2016 Jul 11.
Reference Type
BACKGROUND
Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Jul 20;20(1):227. doi: 10.1186/s12906-020-03013-3.
Reference Type
BACKGROUND
Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006 Oct;32(6):423-36. doi: 10.1016/j.ctrv.2006.05.005. Epub 2006 Jul 24.
Reference Type
BACKGROUND
Longhi A, Reif M, Mariani E, Ferrari S. A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med. 2014;2014:210198. doi: 10.1155/2014/210198. Epub 2014 Mar 31.
Reference Type
BACKGROUND
Longhi A, Cesari M, Serra M, Mariani E. Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. Sarcoma. 2020 Apr 26;2020:8260730. doi: 10.1155/2020/8260730. eCollection 2020.
Reference Type
BACKGROUND
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE; Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095.
Reference Type
BACKGROUND
Olsnes S, Stirpe F, Sandvig K, Pihl A. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem. 1982 Nov 25;257(22):13263-70.
Reference Type
BACKGROUND
Ostermann T, Appelbaum S, Poier D, Boehm K, Raak C, Bussing A. A Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings. Complement Med Res. 2020;27(4):260-271. doi: 10.1159/000505202. Epub 2020 Jan 10.
Reference Type
BACKGROUND
Podlech O, Harter PN, Mittelbronn M, Poschel S, Naumann U. Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med. 2012;2012:501796. doi: 10.1155/2012/501796. Epub 2012 Oct 22.
Reference Type
BACKGROUND
Schoffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A, Wilhelm-Ogunbiyi K, Lentzen H. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer. 2005 Jul;41(10):1431-8. doi: 10.1016/j.ejca.2005.03.019.
Reference Type
BACKGROUND
Stammer RM, Kleinsimon S, Rolff J, Jager S, Eggert A, Seifert G, Delebinski CI. Synergistic Antitumour Properties of viscumTT in Alveolar Rhabdomyosarcoma. J Immunol Res. 2017;2017:4874280. doi: 10.1155/2017/4874280. Epub 2017 Jul 16.
Reference Type
BACKGROUND
Stein GM, Stettin A, Schultze J, Berg PA. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs. 1997 Apr;8 Suppl 1:S57-9. doi: 10.1097/00001813-199704001-00013.
Reference Type
BACKGROUND
Stirpe F, Sandvig K, Olsnes S, Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem. 1982 Nov 25;257(22):13271-7.
Reference Type
BACKGROUND
Timoshenko AV, Cherenkevich SN, Gabius HJ. Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother. 1995;49(3):153-8. doi: 10.1016/0753-3322(96)82609-6.
Reference Type
BACKGROUND
Twardziok M, Kleinsimon S, Rolff J, Jager S, Eggert A, Seifert G, Delebinski CI. Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma. PLoS One. 2016 Sep 2;11(9):e0159749. doi: 10.1371/journal.pone.0159749. eCollection 2016.
Reference Type
BACKGROUND
Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018 Sep;65(9):e27227. doi: 10.1002/pbc.27227. Epub 2018 Jun 19.
Reference Type
BACKGROUND
Weissenstein U, Kunz M, Urech K, Regueiro U, Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med. 2016 Aug 4;16:271. doi: 10.1186/s12906-016-1246-2.
Reference Type
BACKGROUND
U.S. Department of Health and Human Services, Food and Drug Administration,Office of the Commissioner, Good Clinical Practice Program (2008). Guidance for Sponsors, Clinical Investigators, and IRBs Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials. From: https://www.fda.gov/media/75138/download. Accessed 7/22/20.
Reference Type
BACKGROUND
Iscador AG, "ISCADOR in Cancer Therapy: Scientific Information and Study Results", www.iscador.com
Reference Type
BACKGROUND
Iscador AG, "Iscador®P Investigational Medicinal Product Dossier (IMPD)" March, 2020 https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq#_55. Accessed 12/30/19
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro2021-1524
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
NCT01149343
COMPLETED
PHASE1
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
NCT00012064
COMPLETED
PHASE1/PHASE2
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00079144
COMPLETED
PHASE2
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
NCT00199901
COMPLETED
PHASE2
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
NCT00357461
WITHDRAWN
PHASE2
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
NCT06048705
TERMINATED
PHASE1
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
NCT00470379
COMPLETED
EARLY_PHASE1
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
NCT00019383
COMPLETED
PHASE2
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
NCT00005033
COMPLETED
PHASE2
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
NCT00091104
COMPLETED
PHASE1
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
NCT00704938
TERMINATED
PHASE2
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
NCT00091143
COMPLETED
PHASE1
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
NCT01989559
COMPLETED
PHASE1
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
NCT00020397
COMPLETED
PHASE2
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
NCT02015416
COMPLETED
PHASE1
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
NCT00821652
COMPLETED
PHASE1
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
NCT02919449
TERMINATED
PHASE1
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
NCT02122861
COMPLETED
PHASE1
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
NCT02434354
COMPLETED
PHASE1
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
NCT00022438
COMPLETED
PHASE2
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
NCT00961844
TERMINATED
PHASE1/PHASE2
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
NCT06569680
RECRUITING
PHASE2
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019214
COMPLETED
PHASE1/PHASE2
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
NCT00273910
COMPLETED
PHASE2